Introducing the Spring FAST 2016 Companies
Five life science startups, vetted and selected by a distinguished review panel, have been selected for CLSI’s Spring Fellows All-Star Team (FAST) Advisory Program. The Spring 2016 FAST companies are: Circularis, evolving and characterizing improved promoters for increased protein production in cellular expression systems; Eidos, focused on treatment of the orphan disease familial amyloid cardiomyopathy (FAC); Ligandal, developing non-viral nanotechnology to replace the virus in gene therapy and enhance the delivery of genetic tools such as RNA, CRISPR, TALEN, and ZFN; Paragon Genomics, creating breakthrough, easy-to-use, and ultra-high multiplex PCR technology and reagent kits for the Next-Generation Sequencing (NGS) and precision medicine markets; and Shasqi, developers of a highly specific drug delivery system currently focused on chemotherapeutic and antibacterial applications.
Each company founder will be paired with a team of 10 to 12 advisors who will meet with them over 12 weeks for one-hour advisory sessions. These meetings culminate in a final FAST Presentation Showcase in June to a broad audience of industry professionals, entrepreneurs and potential investors.
Now in its third year, FAST was developed to help some of the most innovative young life science companies FAST-track their way to funding and success. In four previous cycles, 24 companies have received over 2400 advisory hours valued at over $620,000, have collectively raised more than $65 million and doubled their headcount since their participation in FAST.
The FAST program draws on a high-level team of serial entrepreneurs, researchers, investors and business advisors with expertise in clinical development, regulatory, reimbursement, relevant technical R&D, finance, marketing and business development. The teams provide FAST entrepreneurs with intensive team review and coaching to perfect their business model and develop a compelling commercialization strategy.